Table 3. Univariable and multivariable analysis of factors affecting local control and overall survival.
| Variable | Local control | Overall survival | |||
|---|---|---|---|---|---|
| Univariable (P) | Multivariable HR (range); P | Univariable (P) | Multivariable HR (range); P | ||
| Sex | <0.001 | 5.7 (0.43–72.4); 0.19 | 0.1 | 0.94 (0.39–2.22); 0.88 | |
| Age ≥65 | 0.32 | 0.8 (0.15–4.39); 0.80 | 0.33 | 0.82 (0.39–1.69); 0.59 | |
| ECOG performance status (0 vs. ≥1) | 0.88 | 2.2 (0.24–19.2); 0.49 | 0.085 | 2.41 (1.01–5.78); 0.041 | |
| CTP score | 0.76 | 1.4 (0.21–9.09); 0.74 | 0.25 | 3.08 (1.51–6.26); 0.002 | |
| BCLC stage | 0.44 | 0.25 (0.02–3.00); 0.27 | 0.13 | 0.64 (0.30–1.35); 0.24 | |
| Pre-SBRT AFP (≥200 ng/mL) | 0.65 | 0.98 (0.16–5.98); 0.98 | 0.002 | 1.34 (0.62–2.91); 0.46 | |
| Pre-SBRT tumor size (≥3 cm) | 0.39 | 0.17 (0.02–1.14); 0.07 | 0.65 | 0.75 (0.37–1.52); 0.42 | |
| Number of prior DEB-TACE to target lesion (1 vs. ≥2) | 0.035 | 0.67 (0.58–104); 0.061 | 0.62 | 0.81 (0.39–1.66); 0.56 | |
| Planned vs. salvage SBRT | 0.052 | 0.17 (0.02–1.67); 0.13 | 0.023 | 0.56 (0.29–1.11); 0.10 | |
| SBRT dose (≥4,000 cGy) | 0.53 | 0.88 (0.15–5.29); 0.75 | 0.42 | 0.45 (0.42–1.89); 0.76 | |
| Transplant (yes vs. no) | 0.015 | 0.01 (0.001–>10); 0.96 | <0.0001 | 0.05 (0.01–0.18); <0.01 | |
SBRT, stereotactic body radiation therapy; DEB, drug eluting bead; TACE, transarterial chemoembolization.